Shares of Axovant Sciences Ltd. (NYSE:AXON) have received a consensus recommendation of “Buy” from the nine brokerages that are covering the firm. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $27.50.
Several research firms have commented on AXON. HC Wainwright reissued a “buy” rating on shares of Axovant Sciences in a report on Wednesday, August 17th. JMP Securities reissued an “outperform” rating and set a $36.00 price objective on shares of Axovant Sciences in a report on Tuesday, August 16th. Zacks Investment Research raised shares of Axovant Sciences from a “hold” rating to a “buy” rating and set a $17.00 price objective for the company in a report on Monday, August 8th. Jefferies Group reissued a “buy” rating and set a $31.00 price objective on shares of Axovant Sciences in a report on Monday, September 26th. Finally, Evercore ISI reaffirmed a “buy” rating and issued a $29.00 price target on shares of Axovant Sciences in a report on Friday, September 23rd.
A number of hedge funds have recently bought and sold shares of the company. Ghost Tree Capital LLC purchased a new stake in Axovant Sciences during the second quarter worth $7,383,000. Citadel Advisors LLC raised its stake in Axovant Sciences by 850.3% in the second quarter. Citadel Advisors LLC now owns 572,679 shares of the company’s stock worth $7,353,000 after buying an additional 512,413 shares during the period. VHCP Management II LLC purchased a new stake in Axovant Sciences during the first quarter worth $4,932,000. BlackRock Fund Advisors raised its stake in Axovant Sciences by 69.2% in the second quarter. BlackRock Fund Advisors now owns 574,250 shares of the company’s stock worth $7,373,000 after buying an additional 234,904 shares during the period. Finally, Sabby Management LLC raised its stake in Axovant Sciences by 458.2% in the second quarter. Sabby Management LLC now owns 190,000 shares of the company’s stock worth $2,440,000 after buying an additional 155,960 shares during the period. 29.45% of the stock is currently owned by institutional investors.
Axovant Sciences (NYSE:AXON) traded down 2.25% on Friday, hitting $13.01. The stock had a trading volume of 200,979 shares. The firm’s market cap is $1.29 billion. The company’s 50 day moving average price is $15.30 and its 200 day moving average price is $13.67. Axovant Sciences has a 52-week low of $8.86 and a 52-week high of $21.30.
Axovant Sciences (NYSE:AXON) last released its quarterly earnings data on Monday, August 15th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.02. Analysts expect that Axovant Sciences will post ($1.68) EPS for the current year.
About Axovant Sciences
Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., is a clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.